CRBU vs. FHTX, PSTX, GLUE, SOPH, CLLS, IMTX, HUMA, INBX, RLAY, and MESO
Should you be buying Caribou Biosciences stock or one of its competitors? The main competitors of Caribou Biosciences include Foghorn Therapeutics (FHTX), Poseida Therapeutics (PSTX), Monte Rosa Therapeutics (GLUE), SOPHiA GENETICS (SOPH), Cellectis (CLLS), Immatics (IMTX), Humacyte (HUMA), Inhibrx (INBX), Relay Therapeutics (RLAY), and Mesoblast (MESO). These companies are all part of the "medical" sector.
Foghorn Therapeutics (NASDAQ:FHTX) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.
Foghorn Therapeutics has a beta of 3.12, meaning that its stock price is 212% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.43, meaning that its stock price is 143% more volatile than the S&P 500.
61.5% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 9.1% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Foghorn Therapeutics has a net margin of -274.23% compared to Foghorn Therapeutics' net margin of -345.05%. Caribou Biosciences' return on equity of 0.00% beat Foghorn Therapeutics' return on equity.
Foghorn Therapeutics received 14 more outperform votes than Caribou Biosciences when rated by MarketBeat users. Likewise, 59.26% of users gave Foghorn Therapeutics an outperform vote while only 52.94% of users gave Caribou Biosciences an outperform vote.
Foghorn Therapeutics has higher earnings, but lower revenue than Caribou Biosciences. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Caribou Biosciences had 7 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 7 mentions for Caribou Biosciences and 0 mentions for Foghorn Therapeutics. Caribou Biosciences' average media sentiment score of 0.00 beat Foghorn Therapeutics' score of -0.68 indicating that Foghorn Therapeutics is being referred to more favorably in the media.
Foghorn Therapeutics currently has a consensus target price of $14.50, indicating a potential upside of 141.26%. Caribou Biosciences has a consensus target price of $15.25, indicating a potential upside of 682.05%. Given Foghorn Therapeutics' higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Foghorn Therapeutics.
Summary
Foghorn Therapeutics and Caribou Biosciences tied by winning 8 of the 16 factors compared between the two stocks.
Get Caribou Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRBU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Caribou Biosciences Competitors List
Related Companies and Tools
